Acute Optic Neuritis Clinical Trial

OCTAGON is the name given to a multicenter clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON). Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss in the optic nerve after a first event of AON.

As study sponsor, Teva Neuroscience is looking for people between the ages of 18 and 45, who have been recently diagnosed with a first event of AON, to participate in this study. Our goal is to match interested volunteers with participating clinical research facilities.

Side effects, some potentially unknown, may be possible.